[1]毛珊珊,张　晗,刘　琨,等.不同剂量布托啡诺预处理对罗库溴铵注射痛的影响[J].新乡医学院学报,2020,37(11):1044-1048.[doi:10.7683/xxyxyxb.2020.11.009]
　MAO Shanshan,ZHANG Han,LIU Kun,et al.Effect of different doses of butorphanol pretreatment on injection pain of rocuronium[J].Journal of Xinxiang Medical University,2020,37(11):1044-1048.[doi:10.7683/xxyxyxb.2020.11.009]
点击复制

不同剂量布托啡诺预处理对罗库溴铵注射痛的影响
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
37
期数:
2020年11
页码:
1044-1048
栏目:
临床研究
出版日期:
2020-11-05

文章信息/Info

Title:
Effect of different doses of butorphanol pretreatment on injection pain of rocuronium
作者:
毛珊珊; 张　晗; 刘　琨; 郑孝振; 陈　勇; 洪道先
（河南大学第一附属医院麻醉与围术期医学科，河南　开封　475001）
Author(s):
MAO Shanshan; ZHANG Han; LIU Kun; ZHENG Xiaozhen; CHEN Yong; HONG Daoxian
(Department of Anesthesiology and Perioperative Medicine,the First Affiliated Hospital of Henan University,Kaifeng 475001,Henan Province,China)
关键词:
布托啡诺; 罗库溴铵; 注射痛; 缩肢反应
Keywords:
butorphanol; rocuronium; injection pain; limb reduction reaction
分类号:
R614
DOI:
10.7683/xxyxyxb.2020.11.009
文献标志码:
A
摘要:
目的　观察预先使用不同剂量的布托啡诺对罗库溴铵注射痛的影响。方法　选择2019年9月至2020年3月河南大学第一附属医院拟行全身麻醉的择期手术患者140例为研究对象，采用计算机随机数字表法将患者分为生理盐水组、10 μg·kg-1布托啡诺组、20 μg·kg-1布托啡诺组及30 μg·kg-1布托啡诺组，每组35例。麻醉诱导前生理盐水组及10、20、30 μg·kg-1布托啡诺组患者分别静脉注射生理盐水5 mL及布托啡诺10、20、30 μg·kg-1（溶入5 mL生理盐水），5 min后各组患者静脉注射罗库溴铵0.6 mg·kg-1。记录患者入手术室时（T0）、注射罗库溴铵前（T1）、注射罗库溴铵后（T2）的平均动脉压（MAP）、心率（HR）；评估各组患者罗库溴铵注射痛、缩肢反应情况；观察注射布托啡诺后不良反应发生情况及术后24 h注射部位疼痛、红肿、水泡、斑块、过敏等不良反应。结果　20、30 μg·kg-1布托啡诺组患者T1时的MAP、HR显著低于T0时（P<0.05）。生理盐水组和10 μg·kg-1布托啡诺组患者T2时的MAP、HR均显著高于T1时（P<0.05）。T1时，30 μg·kg-1布托啡诺组患者MAP显著低于生理盐水组（P<0.05）；T2时，20 μg·kg-1布托啡诺组与30 μg·kg-1布托啡诺组患者MAP、HR显著低于生理盐水组（P<0.05）。10 μg·kg-1布托啡诺组患者罗库溴铵注射痛及缩肢反应发生率与生理盐水组比较差异无统计学意义（χ2=1.607、1.806，P>0.05）。20 μg·kg-1布托啡诺组、30 μg·kg-1布托啡诺组罗库溴铵注射痛及缩肢反应发生率均显著低于生理盐水组和10 μg·kg-1布托啡诺组（χ2=14.570、7.295、27.766、13.027，27.680、17.014、36.187、24.476，P<0.05）；20 μg·kg-1布托啡诺组、30 μg·kg-1布托啡诺组中重度罗库溴铵注射痛发生率显著低于生理盐水组（χ2=23.333、28.810，P<0.05）。20 μg·kg-1布托啡诺组、30 μg·kg-1布托啡诺组患者罗库溴铵注射痛及缩肢反应发生率比较差异无统计学意义（χ2=0.952、1.148，P>0.05）。30 μg·kg-1布托啡诺组不良反应发生率显著高于生理盐水组、10 μg·kg-1布托啡诺组及20 μg·kg-1布托啡诺组（χ2=14.483、11.430、5.185，P<0.05），生理盐水组、10 μg·kg-1布托啡诺组、20 μg·kg-1布托啡诺组患者之间不良反应发生率比较差异均无统计学意义（χ2=1.014、4.242、1.938，P>0.05）。术后24 h，各组患者注射部位均无疼痛、红肿、水泡、斑块、过敏等不良反应。结论　布托啡诺能有效减轻罗库溴铵注射痛，20 μg·kg-1预给剂量相对理想。
Abstract:
Objective　To observe the effect of different doses of butorphinol pretreatment on the injection pain of rocuronium.Methods　A total of 140 patients who underwent elective surgery under general anesthesia in the First Affiliated Hospital of Henan University from September 2019 to March 2020 were selected as the research objects.The patients were randomly divided into the normal saline group,10 μg·kg-1 butorphanol group,20 μg·kg-1 butorphanol group and 30 μg·kg-1 butorphanol group by using the computer random number table method,with 35 cases in each group.Before induction of anesthesia,the patients in the normal saline group and the 10,20,30 μg·kg-1 butorphanol group received intravenous injection of 5 mL of normal saline and 10,20,30 μg·kg-1 of butorphanol (dissolved in 5 mL saline) respectively,5 minutes later,the patients in each group were injected intravenously with rocuronium 0.6 mg·kg-1.The average arterial pressure (MAP) and heart rate (HR) of patients at entering the operating room (T0),before rocuronium injection (T1) and after rocuronium injection (T2) were recorded;the rocuronium injection pain and limb shrinkage reactions of patients in each group were evaluated;the adverse reactions of patients in each group were observed after injection of butorphanol,and other adverse reactions at the injection site were observed at 24 h after operation.Results　The MAP and HR of patients in the 20,30 μg·kg-1 butorphanol groups at T1 were significantly lower than those at T0 (P<0.05).The MAP and HR of patients in the normal saline group and the 10 μg·kg-1 butorphanol group at T2 were significantly higher than those at T1 (P<0.05).The MAP of patients in the 30 μg·kg-1 butorphanol group was significantly lower than that in the normal saline group at T1 (P<0.05);the MAP and HR of patients in the 20,30 μg·kg-1 butorphanol group were significantly lower than those in the saline group at T2 (P<0.05).There was no significant difference in the rocuronium injection pain and the incidence of limb reduction reaction between the 10 μg·kg-1 butorphanol group and the normal saline group (χ2=1.607,1.806;P>0.05).The rocuronium injection pain and the incidence of limb reduction reaction of patients in the 20,30 μg·kg-1 butorphanol group were significantly lower than those in the normal saline group and the 10 μg·kg-1 butorphanol group (χ2=14.570,7.295,27.766,13.027,27.680,17.014,36.187,24.476;P<0.05);the incidence of severe rocuronium injection pain in the 20,30 μg·kg-1 butorphanol group was significantly lower than that in the normal saline group (χ2=23.333，28.810;P<0.05).There was no significant difference in the rocuronium injection pain and the incidence of limb reduction reaction between the 20 μg·kg-1 butorphanol group and 30 μg·kg-1 butorphanol group (χ2=0.952,1.148;P>0.05).The incidence of adverse reactions in the 30 μg·kg-1 butorphanol group was significantly higher than that in the normal saline group and the 10,20 μg·kg-1 butorphanol group (χ2=14.483,11.430,5.185;P<0.05).There was no statistically significant difference in the incidence of adverse reactions of patients among the normal saline group,10,20 μg·kg-1 butorphanol group (χ2=1.014,4.242,1.938；P>0.05).At 24 h after operation,there was no pain,redness,swelling,blisters,plaques,allergies and other adverse reactions at the injection site of patients in each group.Conclusion　Butorphanol can effectively reduce the rocuronium injection pain.The pre-administration dose of 20 μg·kg-1 of butorphanol is relatively ideal.

参考文献/References:

［1］　肖云峰.依达拉奉对急性脑梗死患者的应用分析［J］.中外医学研究，2019，17（4）：153-154.
［2］　TUNG E L,MCTAGGART R A,BAIRD G L,et al.Rethinking thrombolysis in cerebral infarction 2b:which thrombolysis in cerebral infarction scales best define near complete recanalization in the modern thrombectomy era［J］.Stroke,2017,48(9):2488-2493.
［3］　刘雪云，李坦，王濯，等.脑小血管病总体负荷与急性缺血性卒中静脉溶栓后出血转化的关系［J］.中华神经科杂志，2019，52（3）：209-215.
［4］　中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014［J］.中华神经科杂志，2015，48（4）：246-257.
［5］　张磊，刘建民.美国国立卫生研究院卒中量表［J］.中华神经外科杂志，2012，28（5）：455.
［6］　卢寨瑶.Fugl-Meyer量表在脑卒中康复评定中的应用分析［J］.临床医药文献杂志，2016，3（11）：2032-2034.
［7］　赵越，潘永惠.脑卒中患者生存质量量表［J/CD］.中华临床医师杂志：电子版，2013,7（22）：10212-10214.DOI:10.3877/cma.j.issn.1674-0785.2013.22.087.
［8］　KIM D H,LEE D S,NAH H W,et al.Clinical and radiological factors associated with unfavorable outcome after intravenous thrombolysis in patients with mild ischemic stroke［J］.BMC Neurol,2018,30(18):1-8.
［9］　邓立军.重组组织型纤溶酶原激活剂治疗急性脑梗死患者的临床研究［J］.中国临床药理学杂志，2018，34（12）：1398-1400.
［10］　朱珏华，蔡秀英，方琪，等.重组组织型纤溶酶原激活剂静脉溶栓后症状性颅内出血风险评估量表的对比研究［J］.中华神经科杂志，2019，52（12）：1022-1030.
［11］　王涛，贺中正，朱莽，等.依达拉奉对重型颅脑损伤患者急性期脑水肿及神经功能的影响［J］.陕西医学杂志，2017，46（1）：34-36.
［12］　陈娟.尤瑞克林联合依达拉奉治疗急性脑梗死疗效观察［J］.新乡医学院学报，2019，36（1）：60-63.
［13］　杨爽，杨明慧，雷健，等.依达拉奉联合丹红疗法通过调节免疫相关因子表达改善脑梗死［J］.免疫学杂志，2018，34（3）：247-251.
［14］　陈刚.活血通络化痰中药对缺血性脑中风患者临床疗效及血清HCY、CRP、SOD、MDA的影响［J］.标记免疫分析与临床，2017，24（6）：627-630.
［15］　邹荣成，王静，张力.急性缺血性脑卒中病人静脉溶栓后血清白蛋白水平与出血性转化的关系探讨［J］.中西医结合心脑血管病杂志，2019，17（20）：3108-3111.

相似文献/References:

[1]刘湘钰,王晖玥,梁嘉敏,等.新斯的明和抗胆碱药拮抗老年人罗库溴铵残余肌松的合适剂量研究[J].新乡医学院学报,2020,37(1):039.[doi:10.7683/xxyxyxb.2020.01.010]
　LIU Xiangyu,WANG Huiyue,LIANG Jiamin,et al.Appropriate dose of neostigmine and anticholinergic drugs to antagonize rocuronium residual muscle relaxation in the senile patients[J].Journal of Xinxiang Medical University,2020,37(11):039.[doi:10.7683/xxyxyxb.2020.01.010]

更新日期/Last Update: 2020-11-05